Apellis Pharmaceuticals/$APLS

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Apellis Pharmaceuticals

Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.

Ticker

$APLS
Primary listing

Industry

Biotechnology

Employees

708

ISIN

US03753U1060

APLS Metrics

BasicAdvanced
$2.3B
-
-$1.80
0.72
-

What the Analysts think about APLS

Analyst ratings (Buy, Hold, Sell) for Apellis Pharmaceuticals stock.

Bulls say / Bears say

Apellis Pharmaceuticals reported a 97% increase in revenue in 2024, reaching $781.37 million, indicating strong sales growth. (stockanalysis.com)
Analysts have a consensus 'Buy' rating on APLS stock, with a 12-month price target of $39.06, suggesting potential upside of 125.78%. (stockanalysis.com)
The company's drug Syfovre achieved U.S. net product revenue of $611 million in 2024, demonstrating significant market adoption. (seekingalpha.com)
Apellis Pharmaceuticals' stock value was halved after reports of severe inflammation in some patients following treatment with its eye drug. (bloomberg.com)
The European Medicines Agency confirmed its negative opinion on the marketing authorization application of intravitreal pegcetacoplan for treating geographic atrophy, limiting the drug's market potential in Europe. (benzinga.com)
Citron Research issued a short call on Apellis Pharmaceuticals, expressing concerns that the FDA might issue a warning label for Syfovre after a more thorough review. (seekingalpha.com)
Data summarised monthly by Lightyear AI. Last updated on 4 Jun 2025.

APLS Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

APLS Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $APLS

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs